Diverse alterations associated with resistance to KRAS(G12C) inhibition.

Autor: Zhao Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Murciano-Goroff YR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Xue JY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA.; Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA., Ang A; Amgen, Thousand Oaks, CA, USA., Lucas J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Mai TT; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Da Cruz Paula AF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Saiki AY; Amgen, Thousand Oaks, CA, USA., Mohn D; Amgen, Thousand Oaks, CA, USA., Achanta P; Amgen, Thousand Oaks, CA, USA., Sisk AE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Arora KS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Roy RS; Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA., Kim D; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Li C; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA., Lim LP; Resolution Bioscience, Kirkland, WA, USA., Li M; Resolution Bioscience, Kirkland, WA, USA., Bahr A; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Loomis BR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Berger M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Riely G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Arbour KC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lipford JR; Amgen, Thousand Oaks, CA, USA., Li BT; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lito P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA. litop@mskcc.org.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. litop@mskcc.org.; Weill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA. litop@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. litop@mskcc.org.

Publikováno v: Nature [Nature] 2021 Nov; Vol. 599 (7886), pp. 679-683. Date of Electronic Publication: 2021 Nov 10.

Motif-guided identification of KRAS-interacting proteins.

Autor: Wu, Sanan^1,2 (AUTHOR), Gao, Xiaoyang^1,2 (AUTHOR), Wu, Di^1,2 (AUTHOR), Liu, Lu^1,2 (AUTHOR), Yao, Han^3,4,5 (AUTHOR), Meng, Xiangjun^3,4,5 (AUTHOR) meng_xiangjun@yahoo.com, Zhang, Xianglei¹ (AUTHOR) zhangxl6@shanghaitech.edu.cn, Bai, Fang^1,2,6 (AUTHOR) baifang@shanghaitech.edu.cn

Publikováno v: BMC Biology. 11/19/2024, Vol. 22 Issue 1, p1-16. 16p.

Consensus, debate, and prospective on pancreatic cancer treatments.

Autor: Wang, Junke^1,2,3 (AUTHOR), Yang, Jie^4,5 (AUTHOR), Narang, Amol^2,3,6 (AUTHOR), He, Jin^2,3,6,7 (AUTHOR), Wolfgang, Christopher⁸ (AUTHOR), Li, Keyu^2,3,4 (AUTHOR) keyu_li@scu.edu.cn, Zheng, Lei^2,3,6,7,9 (AUTHOR) lzheng6@jhmi.edu

Publikováno v: Journal of Hematology & Oncology. 10/11/2024, Vol. 17 Issue 1, p1-59. 59p.

Discovery of a Covalent Inhibitor of KRAS ^G12C (AMG 510) for the Treatment of Solid Tumors.

Autor: Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, Minatti AE, Nguyen TT, Nishimura N, Pickrell AJ, Reed AB, Shin Y, Siegmund AC, Tamayo NA, Tegley CM, Walton MC, Wang HL, Wurz RP, Xue M, Yang KC, Achanta P, Bartberger MD, Canon J, Hollis LS, McCarter JD, Mohr C, Rex K, Saiki AY, San Miguel T, Volak LP, Wang KH, Whittington DA, Zech SG, Lipford JR, Cee VJ

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Jan 09; Vol. 63 (1), pp. 52-65. Date of Electronic Publication: 2019 Dec 24.

Sotorasib as Fourth-Line Treatment in Pancreatic Cancer: A Case Report and Literature Review.

Autor: ONUKOGU, IFEANYI DAVID¹ ifeanylchukwu.onukogu@chartercare.org, MEDAWAR, GEORGIO², MANGALA, YASHVIN ONKARAPPA³, RATHORE, RITESH¹

Publikováno v: Rhode Island Medical Journal. Jul2024, Vol. 107 Issue 7, p10-13. 4p.